Viridian Therapeutics Inc (VRDN)

$28.77 +0.28 (0.98%)
Market Cap 2.75B
Revenue (ttm) 300,000.00
Net Income (ttm) -269.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89,983.33%
Debt to Equity Ratio 0.04
Volume 2,729,000
Avg Vol 1,287,134
Day's Range N/A - N/A
Shares Out 95.44M
Stochastic %K 93%
Beta 0.72
Analysts Strong Sell
Price Target $41.27

Company Profile

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 272 4600
Fax: 617 272 4601
Address:
221 Crescent Street, Suite 401, Waltham, United States
Tdorsey1776
Tdorsey1776 Nov. 15 at 12:23 AM
$SRRK On the M&A list for 2026 along with $VRDN and $SNDX. GLTA, bio is back baby!!!
0 · Reply
Butch44
Butch44 Nov. 12 at 9:06 PM
$VRDN another solid day on solid volume. Nice steady climb
0 · Reply
MUNEMAKER
MUNEMAKER Nov. 12 at 12:15 AM
$VRDN Almost 2x volume today. Trading like big news is coming soon?
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 11 at 9:08 PM
$VRDN $VRA $VOO $VONE $VOD list 11/07 to 11/21
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 8 at 3:49 PM
$VRDN Three major firms issue Buy ratings on Viridian, citing breakthrough data, de-risked pipeline, and 163% upside potential. https://biotechhealthx.com/biotech-news/heres-why-viridian-therapeutics-vrdn-is-a-strong-buy/
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 4:30 PM
RBC Capital updates rating for Viridian Therapeutics ( $VRDN ) to Outperform, target set at 41 → 45.
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 6 at 3:28 PM
$VRDN Bumping acceptable buyout level over $50...WHO wants to dominate TED? I suspect Biogen is still in the weeds.
0 · Reply
Pika_Capital
Pika_Capital Nov. 6 at 2:51 PM
$VRDN I told you.
1 · Reply
Tdorsey1776
Tdorsey1776 Nov. 6 at 2:42 PM
$VRDN Shorts had their chance to cover low in April, let em roast
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 6 at 2:39 PM
$VRDN SQUEEEEEEEEEEEEEEEEEEZE!!!!!!
0 · Reply
Latest News on VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2025, 7:00 AM EST - 9 days ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Is Ready For An Eventful 2026

Nov 6, 2025, 9:20 AM EST - 10 days ago

Viridian Therapeutics Is Ready For An Eventful 2026

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 5, 2025, 7:01 AM EST - 11 days ago

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

Nov 3, 2025, 7:01 AM EST - 13 days ago

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

Oct 21, 2025, 11:24 PM EDT - 26 days ago

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering

Oct 21, 2025, 4:01 PM EDT - 26 days ago

Viridian Therapeutics Announces Proposed Underwritten Public Offering

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

Oct 20, 2025, 7:30 AM EDT - 27 days ago

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

Viridian Therapeutics: De-Risked Leadership In Thyroid Eye Disease

Sep 26, 2025, 10:56 AM EDT - 7 weeks ago

Viridian Therapeutics: De-Risked Leadership In Thyroid Eye Disease

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

Sep 15, 2025, 7:01 AM EDT - 2 months ago

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results

Aug 7, 2025, 2:37 PM EDT - 3 months ago

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 6:30 AM EDT - 3 months ago

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

Jul 30, 2025, 4:00 AM EDT - 3 months ago

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 3, 2025, 7:00 AM EDT - 4 months ago

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics: The Song Remains The Same

Jun 9, 2025, 6:18 PM EDT - 5 months ago

Viridian Therapeutics: The Song Remains The Same

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

May 30, 2025, 7:00 AM EDT - 6 months ago

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

May 20, 2025, 7:00 AM EDT - 6 months ago

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

May 7, 2025, 4:15 PM EDT - 6 months ago

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

May 6, 2025, 7:00 AM EDT - 6 months ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Apr 7, 2025, 7:00 AM EDT - 7 months ago

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window

Mar 2, 2025, 7:36 AM EST - 9 months ago

Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 9 months ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Jan 8, 2025, 7:00 AM EST - 11 months ago

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)

Dec 19, 2024, 10:34 AM EST - 11 months ago

Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)

Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation

Dec 18, 2024, 10:56 AM EST - 11 months ago

Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation

Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)

Dec 17, 2024, 12:41 PM EST - 11 months ago

Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)

Viridian Therapeutics' eye disorder drug meets late-stage study goal

Dec 16, 2024, 7:10 AM EST - 11 months ago

Viridian Therapeutics' eye disorder drug meets late-stage study goal

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Dec 16, 2024, 7:00 AM EST - 11 months ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Dec 13, 2024, 6:00 PM EST - 1 year ago

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Nov 12, 2024, 7:00 AM EST - 1 year ago

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics' Superior Prospects Make It A Buy

Oct 23, 2024, 4:02 PM EDT - 1 year ago

Viridian Therapeutics' Superior Prospects Make It A Buy

3 Small Biotech Stocks With The 'Big Mo' Right Now

Sep 19, 2024, 12:54 PM EDT - 1 year ago

3 Small Biotech Stocks With The 'Big Mo' Right Now

AUPH CORT

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Sep 11, 2024, 11:25 PM EDT - 1 year ago

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Sep 10, 2024, 5:09 PM EDT - 1 year ago

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Sep 10, 2024, 4:01 PM EDT - 1 year ago

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study

Sep 10, 2024, 7:18 AM EDT - 1 year ago

Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Sep 9, 2024, 4:01 PM EDT - 1 year ago

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 8:15 AM EDT - 1 year ago

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Top 3 Health Care Stocks You May Want To Dump This Quarter

Jul 30, 2024, 10:13 AM EDT - 1 year ago

Top 3 Health Care Stocks You May Want To Dump This Quarter

CPRX VRNA

3 Biotech Names With Potential Catalysts By Year End

Jul 29, 2024, 3:32 PM EDT - 1 year ago

3 Biotech Names With Potential Catalysts By Year End

CADL RCKT

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Jun 12, 2024, 10:29 AM EDT - 1 year ago

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

Jun 11, 2024, 6:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

May 31, 2024, 8:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

May 10, 2024, 8:00 AM EDT - 1 year ago

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call Transcript

May 8, 2024, 2:27 PM EDT - 1 year ago

Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call Transcript

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

May 8, 2024, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

Pacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood Village

May 7, 2024, 7:33 PM EDT - 1 year ago

Pacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood Village

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Tdorsey1776
Tdorsey1776 Nov. 15 at 12:23 AM
$SRRK On the M&A list for 2026 along with $VRDN and $SNDX. GLTA, bio is back baby!!!
0 · Reply
Butch44
Butch44 Nov. 12 at 9:06 PM
$VRDN another solid day on solid volume. Nice steady climb
0 · Reply
MUNEMAKER
MUNEMAKER Nov. 12 at 12:15 AM
$VRDN Almost 2x volume today. Trading like big news is coming soon?
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 11 at 9:08 PM
$VRDN $VRA $VOO $VONE $VOD list 11/07 to 11/21
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 8 at 3:49 PM
$VRDN Three major firms issue Buy ratings on Viridian, citing breakthrough data, de-risked pipeline, and 163% upside potential. https://biotechhealthx.com/biotech-news/heres-why-viridian-therapeutics-vrdn-is-a-strong-buy/
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 4:30 PM
RBC Capital updates rating for Viridian Therapeutics ( $VRDN ) to Outperform, target set at 41 → 45.
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 6 at 3:28 PM
$VRDN Bumping acceptable buyout level over $50...WHO wants to dominate TED? I suspect Biogen is still in the weeds.
0 · Reply
Pika_Capital
Pika_Capital Nov. 6 at 2:51 PM
$VRDN I told you.
1 · Reply
Tdorsey1776
Tdorsey1776 Nov. 6 at 2:42 PM
$VRDN Shorts had their chance to cover low in April, let em roast
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 6 at 2:39 PM
$VRDN SQUEEEEEEEEEEEEEEEEEEZE!!!!!!
0 · Reply
CDMO
CDMO Nov. 6 at 2:37 PM
$VRDN seems like its running away from me😪😎
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 6 at 1:32 PM
$VRDN Successful outperformance is not just picking winners, its position sizing.
0 · Reply
Quantumup
Quantumup Nov. 6 at 11:48 AM
RBC Capital⬆️ $VRDN's PT to $45 from $41, reit'd Outperform, and said, Despite the government shutdown and FDA volatility, VRDN submitted the BLA for veli' late October within prior guidance. $AMGN $RHHBY $DHTRF RBC Capital went on to say:
0 · Reply
Quantumup
Quantumup Nov. 5 at 5:36 PM
Stifel⬆️ $VRDN's PT to $48 from $41 and reiterated at a Buy rating. $AMGN $RHHBY DHTRF Here's what Stifel had to say in its note to investors:
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 5 at 5:24 PM
$VRDN - Completed a comprehensive set of financing transactions in October 2025, securing access to up to $889 million of potential capital across equity, royalty, and credit - ­­ - Successful October submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for veligrotug in thyroid eye disease (TED) and preparing for an anticipated U.S. commercial launch in mid-2026, if approved, under a Priority Review timeline - - Subcutaneous VRDN-003 topline data readout accelerated to Q1 2026 for REVEAL-1 and narrowed to Q2 2026 for REVEAL-2 for active and chronic TED, respectively; each study exceeded its enrollment target due to strong patient demand -
0 · Reply
d_risk
d_risk Nov. 5 at 4:21 PM
$VRDN - Viridian Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors VRDN’s latest 10-Q risk factors spotlight deepening net losses, shrinking cash, urgent need for new capital, and heightened dilution risks. Expanded detail covers regulatory, IP, and operational threats, reliance on third parties, potential for missed milestones, and new risks from government shutdowns, disasters, and macroeconomic volatility. #Biotechnology #MacroeconomicVolatility #CapitalRaising #RegulatoryCompliance #FinancialRisk 🟢 Added 🟠 Removed https://d-risk.ai/VRDN/10-Q/2025-11-05
1 · Reply
Tdorsey1776
Tdorsey1776 Nov. 5 at 4:00 PM
$VRDN Will potential suitors wait? how long??
0 · Reply
FannyPackin
FannyPackin Nov. 5 at 3:41 PM
$VRDN what do we think of chances of BO next year?
1 · Reply
Tdorsey1776
Tdorsey1776 Nov. 5 at 3:01 PM
$VRDN Overview * Viridian Q3 revenue rise driven by license and collaboration revenue * Company secured up to $889 mln in financing, enhancing cash position to $887.9 mln * Submitted BLA for veligrotug to FDA, commercial launch expected mid-2026 if approved Outlook * Viridian expects veligrotug U.S. commercial launch in mid-2026, pending FDA approval * Company anticipates VRDN-003 topline data in Q1 and Q2 2026 * Viridian believes cash and potential revenues will fund plans through profitability
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 4 at 5:52 PM
$SNDX $VRDN $SRRK I must believe these three are on bio M&A lists for 2026. SNDX, SRRK and VRDN top bio M&A targets for 2026 IMO. GLTA
0 · Reply
JarvisFlow
JarvisFlow Nov. 4 at 10:20 AM
BTIG has updated their rating for Viridian Therapeutics ( $VRDN ) to Buy with a price target of 61.
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 3 at 3:45 PM
$VRDN They will dominate the TED market
0 · Reply